Articles tagged "Biopsy"

2022 American Transplant Congress
Development of a Comprehensive Banff Automation System for Kidney Allograft Precision Diagnostics
D. Yoo¹, J. Gueguen¹, G. Divard¹, M. Raynaud¹, V. Goutaudier¹, M. Rabant¹, M. Haas², M. Mengel³, O. Aubert¹, A. Loupy¹
¹Paris Transplant Group, Paris, France, ²Cedars-Sinai Medical Center, Dept. of Pathology, West Hollywood, CA, ³University of Alberta, Edmonton, AB, Canada
*Purpose: Since 1991, the Banff classification has been the gold standard for kidney allograft rejection diagnostics. However, with time, the classification has become complex with…
2022 American Transplant Congress
Re-Examining the Optimal Threshold for Donor Derived Cell Free DNA in Renal Allograft Rejection
H. Murad¹, M. Merzkani¹, M. Ji¹, S. Chang¹, A. Malone¹, R. Delos Santos¹, T. Alhamad²
¹Washington University in St. Louis, St Louis, MO, ²Washington University in St. Louis, Saint Louis, MO
*Purpose: Due to the invasive nature and potential complications of allograft biopsies, there is an important role for surrogate biomarkers to help identify rejection early,…
2022 American Transplant Congress
Three-Way Comparison of Central DSA, %dd-cf DNA, and Molecular Biopsy Findings in the Trifecta Study
P. F. Halloran¹, L. G. Hidalgo², Z. Demko³, A. Prewett³, J. Reeve¹, C. Lawrence⁴, D. Lowe⁴, P. Billings³, .. and the Trifecta Investigators⁵
¹Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, ²University of Wisconsin, Madison, WI, ³Natera Inc., San Carlos, CA, ⁴One Lambda Inc., West Hills, CA, ⁵., ., AB, Canada
*Purpose: Trifecta (ClinicalTrials.gov #NCT04239703) is a prospective, IRB-approved, consented study of the relationships among three central tests in kidney transplant indication biopsies: molecular biopsy diagnoses…
2022 American Transplant Congress
Clinical Stratification of Pediatric Liver Transplant Recipients 4-5 Years Post-Transplant: 1^St Step Towards Personalized Management
W. Dixon¹, E. R. Perito¹, M. Tavakol¹, J. Bucuvalas², S. Feng¹
¹University of California, San Francisco, San Francisco, CA, ²Mount Sinai Kravis Children's Hospital and Recanati/Miller Transplantation Institute, Mount Sinai Health System, New York, NY
*Purpose: Recent surveillance biopsy studies strongly associate high normal ALT (>35U/L) with inflammatory histopathology and low normal ALT (15yrs (n=13; p=0.0006), chronic rejection (CR) diagnosis…
2022 American Transplant Congress
Development and Validation of an Integrative DD-CFDNA System to Predict Allograft Rejection: A Population Based Study
O. Aubert, R. Brousse, J. Gueguen, M. Racape, C. Lefaucheur, A. Loupy
Paris Translational Center for Organ Transplantation, Paris, France
*Purpose: Post-transplantation patient care requires development and validation of non-invasive biomarkers to improve allograft monitoring and prevention from unnecessary and costly biopsies. Reports have suggested…
2022 American Transplant Congress
Can Fibroscan Evaluation Of A Liver Predict Transplantability As Accurately As A Biopsy?
S. J. Sander¹, M. Moncure²
¹Organ Procurement, Midwest Transplant Network, Westwood, KS, ²Midwest Transplant Network, Westwood, KS
*Purpose: Liver transplants are essential procedures that can impact a patient with chronic liver disease’s overall survival. Historically liver biopsies are the gold standard in…
2022 American Transplant Congress
Association Between Allograft Gene Expression and Acute Cellular Rejection Grade in Heart Transplant Recipients
A. Kao¹, K. Haffey², K. T. Gondi³, J. Linard², C. Knutson², K. Morgan², L. Teterina², S. Williams², K. Oreschak⁴, H. Zhang⁴
¹St. Luke's Health System Kansas City Mid America Heart Institute, Kansas City, MO, ²St. Luke's, Kansas City, MO, ³University of Michigan, Ann Arbor, MI, ⁴CareDx, South San Francisco, CA
*Purpose: Endomyocardial biopsy (EMB) remains the gold standard in acute rejection (AR) surveillance in heart transplantation (HT) despite interpretation subjectivity and low concordance rates between…
2022 American Transplant Congress
RNA-Sequencing Analysis of Kidney Allografts Reveal Heightened NK Cell Activity in Chronic Active Antibody-Mediated Rejection
Y. Shah, E. Varma, S. Rahim, C. Li, C. Snopkowski, C. Hughes, D. M. Dadhania, S. Salvatore, S. V. Seshan, O. Elemento, M. Suthanthiran, T. Muthukumar
Weill Cornell Medicine, New York, NY
*Purpose: The role of NK cells is increasingly recognized in chronic active antibody mediated rejection (caABMR) of the kidney allograft. Treatment of caABMR is challenging…
2022 American Transplant Congress
Absolute Quantification of Donor-Derived Cell-Free DNA Does Not Provide Additional Discriminating Power Over Donor-derived Cell-Free DNA Fraction for Detection of Allograft Rejection
R. Gohh¹, S. Jordan², R. N. Woodward³, K. M. Clark-Langone³, J. Morlan³, B. Silva³, M. Weir⁴
¹Alpert School of Medicine Brown University, Providence, RI, ²Cedars Sinai Medical Ctr, Los Angeles, CA, ³CareDx, Redwood City, CA, ⁴University of Maryland School of Medicine, Baltimore, MD
*Purpose: High level of background cell-free DNA (cfDNA) has been hypothesized as a concern for false negative results in molecular diagnostics for allograft rejection that…
2022 American Transplant Congress
Enhanced Histological Yield and Actionable Findings When Biopsy is Guided by Donor-Derived Cell-Free DNA (dd-cfDNA)
M. R. Weir¹, D. Mandelbrot², J. S. Bromberg¹, S. Mehta³, E. Poggio⁴, E. Huang⁵, G. Shekhtman⁶, N. Agrawal⁷, W. Tian⁸, M. Cooper⁹
¹University of Maryland School of Medicine, Baltimore, MD, ²University of Wisconsin, Madison, WI, ³University of Alabama, Birmingham, AL, ⁴Cleveland Clinic, Cleveland, OH, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶CareDx Inc., Brisbane, CA, ⁷CareDx Inc, Brisbane, CA, ⁸CareDx, Brisbane, CA, ⁹MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: Implementation of molecular biomarkers in kidney transplantation has expanded the amount of information available to clinicians before deciding to pursue biopsy. We evaluated how…